Programmed cell Death Ligand 1 (PD-L1) is part of an immune checkpoint system that is essential for preventing autoimmunity. Tumor cells have developed the ability to co-opt these immune checkpoints to suppress anti-tumor immunity. PD-L1 is expressed on tumor cells, tumor associated macrophages (TAMs) and other cells within the microenvironment of the tumor. Immunotherapy using anti-PD-L1 antibody has shown promising anti-tumor effect against a number of cancers including breast cancer, and is currently used in several clinical trials. Furthermore, studies have shown that anti-PD-L1 targeted immunotherapy synergizes with radiation therapy. The aim of this study was to investigate if the therapeutic efficacy of anti-PD-L1 targeted immunotherapy is enhanced when combined with the alpha-particle emitting radiotherapeutic nuclide Actinium-225(225Ac) in a murine immunocompetent metastatic breast cancer model.
NEDROW Jessie;
JOSEFSSON Anders;
PARK Sunju;
BAECK Tom;
HOBBS Robert F.;
BRAYTON Cory;
BRUCHERTSEIFER Frank;
MORGENSTERN Alfred;
SGOUROS G.;
2017-08-01
European Commission - Joint Research Centre
JRC106141
http://nucmed.w3.kanazawa-u.ac.jp/symposium/tat10/,
https://publications.jrc.ec.europa.eu/repository/handle/JRC106141,
| Name | Country | City | Type |
|---|
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Datasets
| ID | Title | Public URL |
|---|
Dataset collections
| ID | Acronym | Title | Public URL |
|---|
Scripts / source codes
| Description | Public URL |
|---|
Additional supporting files
| File name | Description | File type |
|---|